Literature DB >> 33523862

Recessive NOS1AP variants impair actin remodeling and cause glomerulopathy in humans and mice.

Amar J Majmundar1, Florian Buerger1, Thomas A Forbes2,3,4, Verena Klämbt1, Ronen Schneider1, Konstantin Deutsch1, Thomas M Kitzler1,5, Sara E Howden2,3, Michelle Scurr2, Ker Sin Tan2, Mickaël Krzeminski6, Eugen Widmeier1, Daniela A Braun1, Ethan Lai1, Ihsan Ullah1, Ali Amar1, Amy Kolb1, Kaitlyn Eddy1, Chin Heng Chen1, Daanya Salmanullah1, Rufeng Dai1, Makiko Nakayama1, Isabel Ottlewski1, Caroline M Kolvenbach1, Ana C Onuchic-Whitford1,7, Youying Mao1, Nina Mann1, Marwa M Nabhan8, Seymour Rosen9, Julie D Forman-Kay6,10, Neveen A Soliman8, Andreas Heilos11, Renate Kain12, Christoph Aufricht11, Shrikant Mane13, Richard P Lifton13,14, Shirlee Shril1, Melissa H Little2,3, Friedhelm Hildebrandt15.   

Abstract

Nephrotic syndrome (NS) is a leading cause of chronic kidney disease. We found recessive NOS1AP variants in two families with early-onset NS by exome sequencing. Overexpression of wild-type (WT) NOS1AP, but not cDNA constructs bearing patient variants, increased active CDC42 and promoted filopodia and podosome formation. Pharmacologic inhibition of CDC42 or its effectors, formin proteins, reduced NOS1AP-induced filopodia formation. NOS1AP knockdown reduced podocyte migration rate (PMR), which was rescued by overexpression of WT Nos1ap but not by constructs bearing patient variants. PMR in NOS1AP knockdown podocytes was also rescued by constitutively active CDC42Q61L or the formin DIAPH3 Modeling a NOS1AP patient variant in knock-in human kidney organoids revealed malformed glomeruli with increased apoptosis. Nos1apEx3-/Ex3- mice recapitulated the human phenotype, exhibiting proteinuria, foot process effacement, and glomerulosclerosis. These findings demonstrate that recessive NOS1AP variants impair CDC42/DIAPH-dependent actin remodeling, cause aberrant organoid glomerulogenesis, and lead to a glomerulopathy in humans and mice.
Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33523862     DOI: 10.1126/sciadv.abe1386

Source DB:  PubMed          Journal:  Sci Adv        ISSN: 2375-2548            Impact factor:   14.136


  4 in total

Review 1.  Regrow or Repair: An Update on Potential Regenerative Therapies for the Kidney.

Authors:  Melissa H Little; Benjamin D Humphreys
Journal:  J Am Soc Nephrol       Date:  2021-11-17       Impact factor: 10.121

2.  Autonomous Calcium Signaling in Human and Zebrafish Podocytes Controls Kidney Filtration Barrier Morphogenesis.

Authors:  Lydia Djenoune; Ritu Tomar; Aude Dorison; Irene Ghobrial; Heiko Schenk; Jan Hegermann; Lynne Beverly-Staggs; Alejandro Hidalgo-Gonzalez; Melissa H Little; Iain A Drummond
Journal:  J Am Soc Nephrol       Date:  2021-04-28       Impact factor: 14.978

3.  Transplanted organoids empower human preclinical assessment of drug candidate for the clinic.

Authors:  Amy D Westerling-Bui; Eva Maria Fast; Thomas W Soare; Srinivasan Venkatachalan; Michael DeRan; Alyssa B Fanelli; Sergii Kyrychenko; Hien Hoang; Grinal M Corriea; Wei Zhang; Maolin Yu; Matthew Daniels; Goran Malojcic; Xin-Ru Pan-Zhou; Mark W Ledeboer; Jean-Christophe Harmange; Maheswarareddy Emani; Thomas T Tibbitts; John F Reilly; Peter Mundel
Journal:  Sci Adv       Date:  2022-07-06       Impact factor: 14.957

4.  Generation of Monogenic Candidate Genes for Human Nephrotic Syndrome Using 3 Independent Approaches.

Authors:  Verena Klämbt; Youying Mao; Ronen Schneider; Florian Buerger; Hanan Shamseldin; Ana C Onuchic-Whitford; Konstantin Deutsch; Thomas M Kitzler; Makiko Nakayama; Amar J Majmundar; Nina Mann; Hannah Hugo; Eugen Widmeier; Weizhen Tan; Heidi L Rehm; Shrikant Mane; Richard P Lifton; Fowzan S Alkuraya; Shirlee Shril; Friedhelm Hildebrandt
Journal:  Kidney Int Rep       Date:  2020-12-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.